United Kingdom

People: Bellerophon Therapeutics Inc (BLPH.OQ)

BLPH.OQ on NASDAQ Stock Exchange Global Market

16 Aug 2019
Change (% chg)

$0.01 (+0.99%)
Prev Close
Day's High
Day's Low
Avg. Vol
52-wk High
52-wk Low

Peacock, Jonathan 

Mr. Jonathan M. Peacock serves as Chairman of the Board, President of Bellerophon Therapeutics LLC. He was Chief Executive Officer of the Company. Prior to joining us, Mr. Peacock served as the Chief Financial Officer of Amgen Inc., a biotechnology company, from September 2010 to January 2014. From November 2005 to September 2010, he served as Chief Financial and Administrative Officer of Novartis Pharmaceuticals AG, the Pharmaceuticals and Biotechnology division of Novartis AG. Mr. Peacock was a partner at McKinsey and Company, a global strategy consulting firm, from 1998 to 2005. Before that, he was a partner at Price Waterhouse LLP, a global accounting firm (now PricewaterhouseCoopers LLP), from 1993 to 1998. He currently serves on the board of directors of Kite Pharma, Inc., a biopharmaceutical company. Mr. Peacock received an M.A. degree in economics from the University of St. Andrews.

Basic Compensation

Total Annual Compensation, USD 425,539
Restricted Stock Award, USD --
Long-Term Incentive Plans, USD --
All Other, USD 4,529,180
Fiscal Year Total, USD 4,954,720

Options Compensation

  Quantity Market Value
Exercisable -- --
Unexercisable -- --
Exercised -- --